This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
by Zacks Equity Research
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 6.94% and 26.41%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
by Zacks Equity Research
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
by Zacks Equity Research
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
by Zacks Equity Research
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ensign Group Invests in Growth With New Facility Acquisitions
by Zacks Equity Research
ENSG continues its strategic growth with new acquisitions across Washington and California.
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
The latest trading day saw Adma Biologics (ADMA) settling at $20.25, representing a -0.15% change from its previous close.
Centene & HMHB Hawaii Expand Partnership for Maternal Care
by Zacks Equity Research
CNC's Ohana Health Plan and HMHB Hawaii expand maternal care, enhancing support for mothers and babies through strategic investment and community partnerships.
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Here is What to Know Beyond Why ADMA Biologics Inc (ADMA) is a Trending Stock
by Zacks Equity Research
Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
by Zacks Equity Research
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Centene's Meridian Unit Secures a D-SNP Contract in Illinois
by Zacks Equity Research
CNC's Meridian Health Plan wins a D-SNP contract in Illinois, expanding enhanced managed care for Medicare-Medicaid-eligible individuals. The deal is likely to boost Centene's foothold and membership base in the state.
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, Adma Biologics (ADMA) closed at $18.67, indicating a +1.3% shift from the previous trading day.
Will ADMA Biologics Stock Continue Its Momentum in 2025?
by Zacks Equity Research
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Adma Biologics (ADMA) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Look Bullish on Adma Biologics (ADMA): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?